Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-initiated Clinical Study Evaluating the CRISPR-hfCas12Max Gene Editing Therapy in the Treatment of Duchenne Muscular Dystrophy (DMD)

NCT06594094 is registered in ClinicalTrials.gov with HuidaGene Therapeutics Co., Ltd. as lead sponsor.

NCT NCT06594094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06594094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-initiated Clinical Study Evaluating the CRISPR-hfCas12Max Gene Editing Therapy in the Treatment of Duchenne Muscular Dystrophy (DMD)
Lead sponsor
HuidaGene Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 6, 2024
Completion date
June 2, 2027
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophin (dmd)